Phio Pharmaceuticals Corp. announced on December 19, 2024, that its Safety Monitoring Committee (SMC) recommended dose escalation in the Phase 1b clinical trial for PH-762. This positive recommendation allows the study to continue to the third dose cohort, evaluating the safety and tolerability of PH-762 in the treatment of various skin cancers.
The second cohort of the Phase 1b study enrolled four patients diagnosed with cutaneous squamous cell carcinoma. The first two patients who completed treatment demonstrated encouraging results, with one achieving a complete response (100% tumor clearance) and the other a partial response (90% clearance). Pathology data for the remaining two patients in this cohort is forthcoming.
Importantly, the intratumoral injections of PH-762 have been well tolerated by participants, with no dose-limiting toxicities or serious adverse events reported. This consistent safety profile is crucial for advancing the dose-escalation study and supports the continued assessment of PH-762 as a potential treatment for cutaneous carcinomas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.